Cargando…

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

BACKGROUND: Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer. Mutations in the ERBB2 receptor have recently been reported in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kancha, Rama Krishna, von Bubnoff, Nikolas, Bartosch, Natalie, Peschel, Christian, Engh, Richard A., Duyster, Justus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203921/ https://www.ncbi.nlm.nih.gov/pubmed/22046346 http://dx.doi.org/10.1371/journal.pone.0026760

Ejemplares similares

Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation
por: Kancha, Rama Krishna, et al.
Publicado: (2013)

Analysis of Conformational Determinants Underlying HSP90-Kinase Interaction
por: Kancha, Rama Krishna, et al.
Publicado: (2013)

Targeting Oncoprotein Stability Overcomes Drug Resistance Caused by FLT3 Kinase Domain Mutations
por: Yu, Chuanjiang, et al.
Publicado: (2014)

Oncologist’s/haematologist’s view on the roles of pathologists for molecular targeted cancer therapy
por: Keller, Ulrich, et al.
Publicado: (2010)

Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
por: Illert, Anna L., et al.
Publicado: (2014)

Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST)
por: Rassner, Michael, et al.
Publicado: (2023)

HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3
por: Chen, Jhen-Yu, et al.
Publicado: (2015)

ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression
por: Qi, Leilei, et al.
Publicado: (2017)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models
por: Hong, Yong Sang, et al.
Publicado: (2014)

Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation
por: Sigl, M, et al.
Publicado: (2013)

Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review
por: Raja Sharin, Raja Nur Firzanah Syaza, et al.
Publicado: (2022)

Large‐scale pathogenicity prediction analysis of cancer‐associated kinase mutations reveals variability in sensitivity and specificity of computational methods
por: Akula, Sravani, et al.
Publicado: (2023)

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
por: Bekaii-Saab, Tanios, et al.
Publicado: (2006)

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
por: Vogel, Charles, et al.
Publicado: (2010)

Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells
por: Yallowitz, Alisha, et al.
Publicado: (2018)

ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells
por: Li, Dun, et al.
Publicado: (2016)

Longitudinal analysis of cell-free mutated KRAS and CA 19–9 predicts survival following curative resection of pancreatic cancer
por: Hussung, Saskia, et al.
Publicado: (2021)

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway
por: Yang, Zi-Yan, et al.
Publicado: (2020)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance
por: Dong, Hongmei, et al.
Publicado: (2022)

Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
por: Waterhouse, Miguel, et al.
Publicado: (2020)

Correction: Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
por: Waterhouse, Miguel, et al.
Publicado: (2021)

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells
por: Lyu, Hui, et al.
Publicado: (2015)

The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells
por: Komurov, Kakajan, et al.
Publicado: (2012)

Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib
por: Oh, Byeongsang, et al.
Publicado: (2014)

FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27(Kip1) in acute myeloid leukemia
por: Peschel, Ines, et al.
Publicado: (2017)

Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines
por: Wan Mohamad Zain, Wan Nor I′zzah, et al.
Publicado: (2019)

The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition
por: Thakur, Varsha, et al.
Publicado: (2017)

CXCR4, CXCR5 and CD44 May Be Involved in Homing of Lymphoma Cells into the Eye in a Patient Derived Xenograft Homing Mouse Model for Primary Vitreoretinal Lymphoma
por: Babst, Neele, et al.
Publicado: (2022)

Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2
por: Karakashev, Sergey V., et al.
Publicado: (2015)

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
por: Wahdan-Alaswad, Reema, et al.
Publicado: (2020)

Natural Products as Chemopreventive Agents by Potential Inhibition of the Kinase Domain in ErbB Receptors
por: Olivero-Acosta, Maria, et al.
Publicado: (2017)

Identification of lapatinib sensitivity-related genes by integrative functional module analysis
por: Yuan, Qi-Hua, et al.
Publicado: (2020)

APC/C(Cdh1)-Mediated Degradation of the F-Box Protein NIPA Is Regulated by Its Association with Skp1
por: von Klitzing, Christine, et al.
Publicado: (2011)

A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
por: Janni, Wolfgang, et al.
Publicado: (2014)

Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice
por: Ma, Zhikun, et al.
Publicado: (2017)

Photo-Activated Psoralen Binds the ErbB2 Catalytic Kinase Domain, Blocking ErbB2 Signaling and Triggering Tumor Cell Apoptosis
por: Xia, Wenle, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mo8i0c578q9s7638ubnvhcfkcg